Investor Profile: Illumina Ventures — Thesis, Cheque Size & How to Apply

Illumina Ventures is an independently managed, healthcare-focused venture firm launched in 2016 in strategic partnership with Illumina, Inc., the genomics company. Its vision is to unlock the power of the genome, backing early-stage companies that turn breakthrough science into market-leading businesses. For genomics founders, Illumina Ventures funding offers a specialist investor close to a leading genomics tools provider.

Investment thesis

The firm backs companies pioneering new applications of genomics and precision medicine. It looks for technology platforms with broad applicability across several markets, rather than single-product bets, and favours strong teams that can turn deep science into products. Its relationship with Illumina gives portfolio companies access to a leading genomics provider's expertise, alongside the firm's company-building support.

Sectors and stages

Illumina Ventures focuses on life science tools, clinical diagnostics, therapeutics platforms, digital health, and personal wellness. Within those areas it has backed synthetic biology, proteomics, precision medicine, genomics-enabled drug discovery, and next-generation sequencing applications beyond genomics. It invests mainly at Series A and Series B, with selective seed deals, aiming to back roughly 15 to 20 companies per fund, centred on the United States with a growing European presence.

Fund size and cheque size

Illumina Ventures raised a $230 million first fund, anchored by $100 million in seed money from Illumina itself. Its second fund, Illumina Ventures Fund II, closed in September 2021 with total commitments of $325 million, bringing total capital under management at that time to $560 million. The second fund was anchored by Illumina, with most remaining capital from others, including the Ireland Strategic Investment Fund. A standard cheque size is not publicly disclosed.

Notable portfolio

By the close of its second fund, the firm had invested in 25 companies. Named holdings include Twist Bioscience, which synthesises DNA at scale, DNA Script, focused on enzymatic DNA synthesis, Delfi Diagnostics, Kallyope, working on the gut-brain axis, Genome Medical, expanding access to genetic counselling, and LetsGetChecked, in home health testing. Others include Encoded Therapeutics and SQZ Biotech.

Partners

Illumina Ventures was founded by Nick Naclerio, its founding partner, who previously served as Illumina's senior vice president of corporate and venture development and co-founded or led several diagnostic firms, including Quanterix and ParAllele Bioscience. He has described the firm's approach as backing great teams with platform technologies serving multiple markets. Malek Faham serves as chief scientist, reflecting the centrality of technical diligence.

Programs, credits and perks

Illumina Ventures does not publish a standing accelerator with fixed cohorts or a startup credits catalogue, and founders should not assume one exists. Its most visible programme-style activity is ecosystem support for genomics innovation, including the Irish Genomics Business Plan Competition, whose winners received access to Illumina sequencing consumables and technical expertise, strategic mentorship from Illumina Ventures, intellectual property guidance, and legal support. The real perk is proximity to Illumina's scientific network.

How to apply for funding

There is no open application portal, so learning how to get funding from Illumina Ventures means a targeted, science-led approach. Reach the firm through its website contact route or, better, through a warm introduction from a genomics founder, scientific adviser, or co-investor in its orbit. Lead with the science: what the platform does, why it is broadly applicable, what evidence exists, and what the next milestone unlocks.